Is Ribociclib a targeted drug?

Ribociclib (Ribociclib) is a targeted drug. It belongs to a class of drugs called CDK4/6 inhibitors, which are used to treat hormone receptor-positive, HER2-negative metastatic breast cancer. Riboxiclib targets the proteins cyclin-dependent kinase 4 and cyclin-dependent 6 (CDK 4 and CDK 6) on breast cancer cells. CDK 4 and CDK 6 are proteins that stimulate cancer cells to divide and grow. Riboxil works by blocking these proteins, which is designed to slow or stop cancer growth. This drug is often used in combination with other anticancer drugs to increase the effectiveness of the treatment.

Many cancer cells exhibit abnormalities that increaseCDK activity, leading to the inactivation of certain tumor suppressor genes. When combined with other drugs such as ALK or MEK inhibitors, the ribose ring has been shown to act synergistically, resulting in improved response. Again, this may be the result of "crosstalk" between signaling pathways. By blocking several pathways simultaneously, tumors are thought to be less able to compensate, and greater antitumor responses are often observed. Use of RiboCycle in combination with other agents has been shown to reduce the development of resistance to these agents.

The original drug Riboxil has been launched in China, but due to its short time on the market, its price and purchase methods are not yet known, and it has not yet been included in the scope of medical insurance. The price of the European version of Riboxil's original drug, 200mg*21 tablets, sold overseas may be more than RMB 20,000 per box, while the Indian version of Riboxil's original drug, 200mg*21 tablets, may be priced around RMB 3,000 per box (the price may fluctuate due to exchange rates). The ingredients of the two drugs are basically the same. There are currently no generic versions of Riboxil produced and marketed.